Psoriasis

Psoriasis – Improving patient outcomes through topical management in primary care

Date: Part 1: Insight session : 17th November 2021, Part 2: Implementation session : 24th November 2021, QI POD session: 1st December 2021

Cost: Free

Virtual Workshops 20:00 - 21:30

This promotional psoriasis programme including educational resources, virtual workshops and implementation resources has been developed by Soar Beyond and LEO Pharma. The programme is fully funded by LEO Pharma and is intended for UK Healthcare Professionals only.

The intended audience is clinical pharmacists working in general practice wanting to set up and deliver a psoriasis review clinic. This training is to be used as a guide only and should be used to augment local guidelines and pathways. Pharmacists are encouraged to link with a GP prescribing / dermatology lead for supervision and mentorship to support clinical competence. Please note that the scope of the Soar Beyond i2i resources is for psoriasis only and it is not advisable that non-specialists manage other types of dermatological conditions.

Treatment options will be discussed as part of this programme. Treatment options will be discussed at the meeting, Enstilar® (calcipotriol/betamethasone dipropionate) and Dovobet® (calcipotriol/betamethasone dipropionate) Gel and Ointment Prescribing information and adverse reporting can be found here.

Reporting of Suspected Adverse Reactions

Adverse events should be reported.

Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Drug Safety at LEO Pharma by calling +44 (0)1844 347333 or e-mail: [email protected]

The i2i network is delighted to launch our psoriasis programme as a 3 part programme over three consecutive weeks. This means that in three weeks, with the support of our e-learning, you can rapidly grow confidence and competence in managing psoriasis for your patient populations

Psoriasis management in primary care can help to reduce inappropriate referrals to secondary care and reduce the pressure on the NHS. The role of the GP pharmacist is essential to help to ensure that patients receive annual reviews in relation to their psoriasis and that medicines are not just re-authorised without a thorough review.

Speakers

Stephanie Gallard

Dr Stephanie Gallard qualified as a pharmacist in 1991, a doctor in 1996, a GP in 2003, and after several years as a salaried GP moved into medical management in 2008.  Following several deputy medical director roles, she decided in 2018 to return to the primary care front line as a “proper” GP again and renew her acquaintance with patients!

 

Read Bio
Dianne Sanderson

Dianne is an independent prescriber working as a senior clinical pharmacist within a GP practice and a mentor to other pharmacists within the PCN. Dianne also works as a dermatology pharmacist within a community based specialist dermatology service.

 

Read Bio
Dominika Froehlich-Jeziorek

Dominika is a senior pharmacist and a pharmacy team lead at Fernbank Surgery in Lytham, Lancashire. She has extensive experience across community pharmacy, medicines management and primary care, including care homes. Her clinical interests are focused on the management of respiratory diseases, chronic pain and dermatological conditions.

Read Bio

Agenda

 

By participating in this programme, you will:

  1. Understand the pathophysiology of psoriasis and the impact on patient quality of life (QoL) and the NHS
  2. Have an overview of the treatment and management options in primary care including adopting a patient centred holistic approach
  3. Know how to advance psoriasis treatments in patients to improve patient QoL
  4. Learn how to run effective psoriasis annual reviews as part of your structured medication reviews (SMRs) and improve patient outcomes in relation to their psoriasis

Supported by

sponsor

This promotional psoriasis programme including educational resources, virtual workshops and implementation resources has been developed by Soar Beyond and LEO Pharma. The programme is fully funded by LEO Pharma and is intended for UK Healthcare Professionals only.

The intended audience is clinical pharmacists working in general practice wanting to set up and deliver a psoriasis review clinic. This training is to be used as a guide only and should be used to augment local guidelines and pathways. Pharmacists are encouraged to link with a GP prescribing / dermatology lead for supervision and mentorship to support clinical competence. Please note that the scope of the Soar Beyond i2i resources is for psoriasis only and it is not advisable that non-specialists manage other types of dermatological conditions.

Treatment options will be discussed as part of this programme. Treatment options will be discussed at the meeting, Enstilar® (calcipotriol/betamethasone dipropionate) and Dovobet® (calcipotriol/betamethasone dipropionate) Gel and Ointment Prescribing information and adverse reporting can be found here.

Reporting of Suspected Adverse Reactions

Adverse events should be reported.

Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Drug Safety at LEO Pharma by calling +44 (0)1844 347333 or e-mail: [email protected]

Click here to report an adverse event

Job bag : MAT-51249 V2

Date of preparation : November 2021

Hide

Health Care Professionals Attend An Event

Book onto an event as a healthcare professional
  • All communication will be received through this email.
  • This field is for validation purposes and should be left unchanged.